Literature DB >> 20555068

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

J-L Harousseau1, M Dreyling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20555068     DOI： 10.1093/annonc/mdq178

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  19 in total

1.  Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

Authors:  Paul G Richardson; Sundar Jagannath; Philippe Moreau; Andrzej J Jakubowiak; Marc S Raab; Thierry Facon; Ravi Vij; Darrell White; Donna E Reece; Lotfi Benboubker; Jeffrey Zonder; L Claire Tsao; Kenneth C Anderson; Eric Bleickardt; Anil K Singhal; Sagar Lonial
Journal:  Lancet Haematol       Date:  2015-11-16       Impact factor: 18.959

2.  Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.

Authors:  Bernard Regidor; Marissa-Skye Goldwater; Jessica Wang; Sean Bujarski; Regina Swift; Benjamin Eades; Marsiye Emamy-Sadr; Shahrooz Eshagian; Gary Schwartz; Tanya M Spektor; James R Berenson
Journal:  Ann Hematol       Date:  2021-05-14       Impact factor: 3.673

3.  Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study.

Authors:  Matthias Naegele; Monika Kirsch; Gabriele Ihorst; Katharina Fierz; Monika Engelhardt; Sabina De Geest
Journal:  Support Care Cancer       Date:  2017-09-16       Impact factor: 3.603

Review 4.  Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.

Authors:  Lesley J Scott; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

5.  Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.

Authors:  Shinsuke Iida; Hirokazu Nagai; Gen Kinoshita; Masafumi Miyoshi; Michael Robbins; Dimple Pandya; Eric Bleickardt; Takaaki Chou
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

6.  Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.

Authors:  April Teitelbaum; Abbie Ba-Mancini; Hui Huang; Henry J Henk
Journal:  Oncologist       Date:  2013-01-08

7.  Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.

Authors:  Bernard Regidor; Regina Swift; Benjamin Eades; Marsiye Emamy-Sadr; Fadi Tarhini; Tanya M Spektor; James R Berenson
Journal:  Ann Hematol       Date:  2020-11-25       Impact factor: 3.673

8.  Multiple myeloma presenting as plasmacytoma of the jaws showing prominent bone formation during chemotherapy.

Authors:  S-Y An; C-H An; K-S Choi; M-S Heo
Journal:  Dentomaxillofac Radiol       Date:  2013       Impact factor: 2.419

Review 9.  Pomalidomide: a review of its use in patients with recurrent multiple myeloma.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 10.  Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.